Subscribe
shutterstock_609476021_ken_wolter
Ken Wolter / Shutterstock.com
25 April 2019Generics

Insurer accuses Janssen of sham lawsuits to stop cancer generic

A US health insurance provider is suing a subsidiary of Johnson & Johnson for filing “sham” patent litigation in a bid to stop generic forms of a prostate cancer treatment from entering the market.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Big Pharma
City of Baltimore accuses Janssen of delaying generics
23 May 2019   Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is being sued for “unlawfully” delaying generic competition to Zytiga, its branded cancer medication.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Big Pharma
City of Baltimore accuses Janssen of delaying generics
23 May 2019   Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is being sued for “unlawfully” delaying generic competition to Zytiga, its branded cancer medication.

More on this story

Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Big Pharma
City of Baltimore accuses Janssen of delaying generics
23 May 2019   Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is being sued for “unlawfully” delaying generic competition to Zytiga, its branded cancer medication.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent